Pomerantz Law Firm Investigates Securities Fraud Claims Against Soleno Therapeutics, Inc.
On September 18, 2025, Pomerantz LLP announced that it is currently investigating potential claims related to securities fraud on behalf of investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO). This investigation stems from allegations that the company and its executives may have participated in unlawful business practices that could have impacted share prices negatively.
The investigation follows a concerning report published on August 15, 2025, by Scorpion Capital. In this report, Scorpion criticized Soleno’s primary product, Vykat XR, claiming it was overpriced and raised safety concerns, particularly for pediatric patients. This report led to a significant drop in Soleno's stock price, falling by $5.73 per share, equivalent to a 7.41% decrease, closing at $71.63 the same day.
Pomerantz LLP encourages any investors who may have been affected by these developments to reach out. Legal representatives are specifically looking for individuals who purchased Soleno shares during this problematic time. Those interested can contact Danielle Peyton either via email at [email protected] or by phone at 646-581-9980, ext. 7980.
For context, Pomerantz LLP is highly regarded in the legal field for its work in corporate, securities, and antitrust class litigation. Founded by Abraham L. Pomerantz, often referred to as the 'dean of the class action bar', the firm has been operating for over 85 years, advocating for the rights of investors victimized by fraud and corporate misconduct. Their extensive track record includes recovering substantial damages for clients affected by such illegal activities.
The firm has a global presence with offices in cities like New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, demonstrating their extensive reach and commitment to investor rights. It is important to note that while past successes are notable, they do not guarantee future results in ongoing cases.
Investors who believe their shares have been impacted or who have additional information regarding the company’s business practices are advised to take proactive measures. Collecting relevant documentation regarding their investment in Soleno Therapeutics could be crucial moving forward. Joining the Pomerantz class action may provide not only a potential financial recourse but also bring attention to the need for accountability in corporate practices.
The investigation by Pomerantz LLP signifies a serious look into the practices and claims surrounding Soleno Therapeutics. With the substantial fallout from the recent allegations, it is essential for investors to stay informed and explore their legal options. Keeping abreast of further developments as this case unfolds could be invaluable for those affected. Investors are urged to act quickly and utilize available resources to safeguard their interests in the wake of troubling news about Soleno’s operations. For more information about the firm and to explore further details regarding their investigations, you can visit their website at www.pomlaw.com.
Background of the Investigation
The investigation follows a concerning report published on August 15, 2025, by Scorpion Capital. In this report, Scorpion criticized Soleno’s primary product, Vykat XR, claiming it was overpriced and raised safety concerns, particularly for pediatric patients. This report led to a significant drop in Soleno's stock price, falling by $5.73 per share, equivalent to a 7.41% decrease, closing at $71.63 the same day.
Pomerantz LLP encourages any investors who may have been affected by these developments to reach out. Legal representatives are specifically looking for individuals who purchased Soleno shares during this problematic time. Those interested can contact Danielle Peyton either via email at [email protected] or by phone at 646-581-9980, ext. 7980.
Pomerantz LLP's Role
For context, Pomerantz LLP is highly regarded in the legal field for its work in corporate, securities, and antitrust class litigation. Founded by Abraham L. Pomerantz, often referred to as the 'dean of the class action bar', the firm has been operating for over 85 years, advocating for the rights of investors victimized by fraud and corporate misconduct. Their extensive track record includes recovering substantial damages for clients affected by such illegal activities.
The firm has a global presence with offices in cities like New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, demonstrating their extensive reach and commitment to investor rights. It is important to note that while past successes are notable, they do not guarantee future results in ongoing cases.
Investor Action Steps
Investors who believe their shares have been impacted or who have additional information regarding the company’s business practices are advised to take proactive measures. Collecting relevant documentation regarding their investment in Soleno Therapeutics could be crucial moving forward. Joining the Pomerantz class action may provide not only a potential financial recourse but also bring attention to the need for accountability in corporate practices.
Conclusion
The investigation by Pomerantz LLP signifies a serious look into the practices and claims surrounding Soleno Therapeutics. With the substantial fallout from the recent allegations, it is essential for investors to stay informed and explore their legal options. Keeping abreast of further developments as this case unfolds could be invaluable for those affected. Investors are urged to act quickly and utilize available resources to safeguard their interests in the wake of troubling news about Soleno’s operations. For more information about the firm and to explore further details regarding their investigations, you can visit their website at www.pomlaw.com.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.